- •
Peripartum cardiomyopathy (PPCM) is a complication of late pregnancy and the early postpartum period characterized by dilated cardiomyopathy and heart failure with reduced ejection fraction.
- •
Although the prevalence of specific arrhythmias in PPCM is unknown, an estimated 1 in 4 deaths in women with this condition is sudden and presumed secondary to ventricular tachyarrhythmia.
- •
Management of PPCM entails standard treatment of heart failure with reduced ejection fraction and prevention of sudden
Arrhythmias in Peripartum Cardiomyopathy
Section snippets
Key points
Arrhythmias in peripartum cardiomyopathy
Atrial and ventricular arrhythmias are common in patients with heart failure and cardiomyopathy.21 Data on arrhythmia associated specifically with PPCM are sparse, and underlying mechanisms are unclear (Fig. 3). Available data are limited to case reports and small case series, which are summarized in Table 1. In a series of 19 patients in Senegal with PPCM who underwent 24-hour continuous electrocardiographic monitoring, 89% had sinus tachycardia, 37% had premature ventricular contractions, 21%
Medical Management
Some women who develop arrhythmias secondary to PPCM may require intravenous antiarrhythmic drugs (AADs) in the acute setting or oral AADs for chronic management. In women requiring AADs prior to delivery, consideration must be given to the effects of AADs on fetal heart rhythm, fetal growth, and uterine activity.23
There is a dearth of data on the risk of AADs to the fetus in pregnancy. As a result, most AADs are Food and Drug Administration (FDA) pregnancy category C (risk cannot be ruled
Summary
Peripartum cardiomyopathy is a potentially life-threatening complication of pregnancy, occurring in the final month of gestation or up to 5 months postpartum. Management entails standard therapies for heart failure with reduced ejection fraction, with some exceptions in the antepartum period. Patients are at risk for arrhythmias and SCD. Much remains unknown about PPCM. In particular, further research is needed to elucidate the prevalence, underlying mechanism, and natural history of
References (43)
Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management
J Am Coll Cardiol
(2011)- et al.
B-type natriuretic peptide in pregnant women with heart disease
J Am Coll Cardiol
(2010) - et al.
African-American women have a higher risk for developing peripartum cardiomyopathy
J Am Coll Cardiol
(2010) - et al.
Characteristics, adverse events, and racial differences among delivering mothers with peripartum cardiomyopathy
JACC Heart Fail
(2013) - et al.
Incidence, mortality, and racial differences in peripartum cardiomyopathy
Am J Cardiol
(2007) - et al.
Frequency of peripartum cardiomyopathy
Am J Cardiol
(2006) - et al.
Peripartum cardiomyopathy: predictors of recovery and current state of implantable cardioverter-defibrillator use
J Am Coll Cardiol
(2014) - et al.
Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome
Am J Obstet Gynecol
(2008) - et al.
Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers
Int J Gynaecol Obstet
(2010) Sudden cardiac death is still a risk for some peripartum cardiomyopathy mothers
J Card Fail
(2012)
Cardiac arrhythmias in pregnancy
Semin Perinatol
Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section
BJOG
Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival
J Am Coll Cardiol
Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator
J Card Fail
Evolution and thromboembolic complications of the idiopathic peripartal cardiomyopathy at Dakar University Hospital: forward-looking study about 33 cases
J Gynecol Obstet Biol Reprod (Paris)
Case 1—2002—a patient with severe peripartum cardiomyopathy and persistent ventricular fibrillation supported by a biventricular assist device
J Cardiothorac Vasc Anesth
Familial occurrence of peripartum cardiomyopathy
Am Heart J
ESC guidelines on the management of cardiovascular diseases during pregnancy: the task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC)
Eur Heart J
Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review
JAMA
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology working group on peripartum cardiomyopathy
Eur J Heart Fail
Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy
Heart
Cited by (0)
The authors report no conflicts of interest.